Led · Series D · Aug 2026

Renata Medical develops cardiovascular devices purpose-built for neonates, infants, and young children with congenital heart disease. Its lead product, the Minima™ Stent System, is the first balloon-expandable growth stent designed specifically for pediatric patients with pulmonary artery stenosis or coarctation of the aorta; it received FDA premarket approval in August 2024 and a CMS NTAP designation in August 2025. Minima launched commercially in 2024 and the company reports adoption has exceeded expectations across leading congenital heart programs. Renata plans to use the Series D proceeds to expand U.S. commercialization, enter international markets, advance its pediatric CHD technology pipeline, and support ongoing clinical evidence generation. The company was founded in 2019 and is incorporated in Delaware.

Participated · Seed · May 2025

Turtle has built a liquidity distribution protocol that curates opportunities, consolidates liquidity, and routes it to DeFi partners via a data-driven coordination layer. The platform currently serves an expanding network, linking more than 358,000 wallets and routing over $5.5 billion in liquidity. To date, the company has generated more than $6 million in revenue, illustrating the sustainability of its model compared with short-term incentive schemes. Led by CEO Essi Lagevardi, Turtle is now focusing on accelerating the rollout of its Earn infrastructure, enlarging its engineering team, and deepening multi-chain integrations. The recent capital injection lifts its total external funding to $11.7 million. These resources are intended to fuel further product development and ecosystem expansion across multiple blockchains.